Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4335

1.

Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials.

Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L.

Cancer Sci. 2019 Jan 21. doi: 10.1111/cas.13947. [Epub ahead of print]

PMID:
30663191
2.

Nitric oxide inhibits autophagy and promotes apoptosis in hepatocellular carcinoma.

Zhang X, Jin L, Tian Z, Wang J, Yang Y, Liu J, Chen Y, Hu C, Chen T, Zhao Y, He Y.

Cancer Sci. 2019 Jan 18. doi: 10.1111/cas.13945. [Epub ahead of print]

3.

Roles of EphA1/A2 and ephrin-A1 in cancer.

Ieguchi K, Maru Y.

Cancer Sci. 2019 Jan 18. doi: 10.1111/cas.13942. [Epub ahead of print] Review.

4.

Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.

Sakai Y, Miyazawa M, Komura T, Yamada T, Nasti A, Yoshida K, Takabatake H, Yamato M, Yamashita T, Yamashita T, Mizukoshi E, Okuzono M, Ho TTB, Kawaguchi K, Wada T, Honda M, Kaneko S.

Cancer Sci. 2019 Jan 18. doi: 10.1111/cas.13944. [Epub ahead of print]

5.

REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2.

Gu C, Luo J, Lu X, Tang Y, Ma Y, Yun Y, Cao J, Cao J, Huang Z, Zhou X, Zhang S.

Cancer Sci. 2019 Jan 18. doi: 10.1111/cas.13946. [Epub ahead of print]

6.

Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer.

Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T.

Cancer Sci. 2019 Jan 18. doi: 10.1111/cas.13943. [Epub ahead of print]

7.

Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib.

Morii I, Iwabuchi Y, Mori S, Suekuni M, Natsume T, Yoshida K, Sugimoto N, Kanemaki MT, Fujita M.

Cancer Sci. 2019 Jan 16. doi: 10.1111/cas.13941. [Epub ahead of print]

8.

Bazedoxifene exhibits growth suppressive activity by Targeting IL-6/GP130/STAT3 Signaling in Hepatocellular Carcinoma.

Ma H, Yan D, Wang Y, Shi W, Liu T, Zhao C, Huo S, Duan J, Tao J, Zhai M, Luo P, Guo J, Tian L, Mageta L, Jou D, Zhang C, Li C, Lin J, Lv J, Li S, Lin L.

Cancer Sci. 2019 Jan 16. doi: 10.1111/cas.13940. [Epub ahead of print]

9.

Shortcuts to Intestinal Carcinogenesis by Genetic Engineering in Organoids.

Maru Y, Onuma K, Ochiai M, Imai T, Hippo Y.

Cancer Sci. 2019 Jan 13. doi: 10.1111/cas.13938. [Epub ahead of print] Review.

10.

Differential regulation of CpG island-methylation within divergent and unidirectional promoters in colorectal cancer.

Namba S, Sato K, Kojima S, Ueno T, Yamamoto Y, Tanaka Y, Inoue S, Nagae G, Iinuma H, Hazama S, Ishihara S, Aburatani H, Mano H, Kawazu M.

Cancer Sci. 2019 Jan 13. doi: 10.1111/cas.13937. [Epub ahead of print]

11.

ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.

Mase S, Shinjo K, Totani H, Katsushima K, Arakawa A, Takahashi S, Lai HC, Lin RI, Chan MWY, Sugiura-Ogasawara M, Kondo Y.

Cancer Sci. 2019 Jan 11. doi: 10.1111/cas.13936. [Epub ahead of print]

12.

UNC5D, suppressed by promoter hypermethylation, inhibits cell metastasis by activating DAPK1 in prostate cancer.

Dong D, Zhang L, Bai C, Ma N, Ji W, Jia L, Zhang A, Zhang P, Ren L, Zhou Y.

Cancer Sci. 2019 Jan 11. doi: 10.1111/cas.13935. [Epub ahead of print]

13.

Optimal therapeutic strategy using antigen-containing liposomes selectively delivered to antigen-presenting cells.

Iyoda T, Yamasaki S, Kawamura M, Ueda M, Son K, Ito Y, Shimizu K, Fujii SI.

Cancer Sci. 2019 Jan 10. doi: 10.1111/cas.13934. [Epub ahead of print]

14.

Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation.

Harada K, Ihara F, Takami M, Kamata T, Mise N, Yoshizawa H, Hishiki T, Saito T, Terui K, Nakata M, Komatsu S, Ikeuchi T, Nakayama T, Yoshida H, Motohashi S.

Cancer Sci. 2019 Jan 10. doi: 10.1111/cas.13933. [Epub ahead of print]

15.

KEYNOTE-025: Phase 1b Study of Pembrolizumab in Japanese Patients With Previously Treated PD-L1-Positive Advanced NSCLC.

Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T.

Cancer Sci. 2019 Jan 7. doi: 10.1111/cas.13932. [Epub ahead of print]

16.

The p53/LDHA axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53.

Zhou Y, Niu W, Luo Y, Li H, Xie Y, Wang H, Liu Y, Fan S, Li Z, Xiong W, Li X, Ren C, Tan M, Li G, Zhou M.

Cancer Sci. 2019 Jan 7. doi: 10.1111/cas.13928. [Epub ahead of print]

17.

Preclinical pharmacodynamics evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.

Yang W, Meng L, Chen K, Tian C, Peng B, Zhong L, Zhang C, Yang X, Zou J, Yang S, Li L.

Cancer Sci. 2019 Jan 7. doi: 10.1111/cas.13929. [Epub ahead of print]

18.

PIK3CD induces cell growth and invasion by activating AKT/GSK-3β/β-catenin signaling in colorectal cancer.

Chen JS, Huang JQ, Luo B, Dong SH, Wang RC, Jiang ZK, Xie YK, Yi W, Wen GM, Zhong JF.

Cancer Sci. 2019 Jan 8. doi: 10.1111/cas.13931. [Epub ahead of print]

19.

Population-Based Cohort Study on Health Effects of Asbestos Exposure in Japan.

Zha L, Kitamura Y, Kitamura T, Liu R, Shima M, Kurumatani N, Nakaya T, Goji J, Sobue T.

Cancer Sci. 2019 Jan 7. doi: 10.1111/cas.13930. [Epub ahead of print]

20.

Genome-wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma.

Nakamura T, Fukuoka K, Nakano Y, Yamasaki K, Matsushita Y, Yamashita S, Ikeda J, Udaka N, Tanoshima R, Shiba N, Tateishi K, Yamanaka S, Yamamoto T, Hirato J, Ichimura K.

Cancer Sci. 2019 Jan 4. doi: 10.1111/cas.13903. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center